Clinical Trials Search
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma
In this response adapted approach, older adults with newly diagnosed symptomatic multiple myeloma will receive daratumumab and dexamethasone for 2 months. Patients who achieve a partial response or better will continue on daratumumab. Patients who achieve less than a partial response will have lenalidomide or bortezomib added to their therapy. Patients who experience progressive disease on daratumumab after the initial 2 months of monotherapy or on the combination of daratumumab and either lenalidomide or bortezomib will come off study.
To evaluate the efficacy of a daratumumab based response adapted approach Secondary: To evaluate the safety profile of daratumumab based therapy in older adults with newly diagnosed myeloma. To identify potential biomarkers for the prediction of response to therapy in MM
Bortezomib (); CC-5013 (Lenalidomide); Daratumumab (); Dexamethasone (); Lenalidomide (Revlimid); PS-341 (Bortezomib); Velcade (Bortezomib)